#LCSM

#LCSM Chat 01/25: Open Mic Nite–What’s on your mind?

Unknown

On Thursday January 25, 2018, at 8 PM Eastern (5 PM Pacific), #LCSM Chat will hold an Open Mic Nite to talk about whatever lung cancer topics are foremost on our minds. This would be a particularly good chat for those who are just starting with Twitter or tweet chats (please check out our tweetchat primer). Janet Freeman-Daily will moderate.
Please join us!

#LCSM Chat Topic 1/11: Defining “hope” for lung cancer

Ten years ago, patients diagnosed with lung cancer did not have much hope for effective treatment. Now targeted therapy, immunotherapy, and other treatment innovations offer hope that many more lung cancer patients might live for years beyond the old survival expectations.

Yet even with all the advances in medical care, not all lung cancer patients have access to the best treatment options, metastatic lung cancer patients are still not curable, and lung cancer patients still die.

Does this mean we have no hope?  No!

Hope means a lot of things. Hope can be as simple as finding comfort in the face of pain, or looking for the good in each day despite dire circumstances—it gives the person some control amidst the unknown. You beat cancer by how you live—that’s a win regardless of the health outcome. In contrast, false hope is telling someone that something will come true when you can’t know whether it will happen; in the world of metastatic cancer, such “hope” often leads people to make different choices than they might have made had they known the truth, and they might lose some valuable living time in the process.

Please join us on January 11 at 8 PM Eastern, 5 PM Pacific, for our next #LCSM chat, where moderator Janet Freeman-Daily (@JFreemanDaily) will lead our discussion about defining hope using the following questions:

  • T1: How do you define “hope” for lung cancer? Does the definition differ for patients, caregivers, doctors, researchers?
  • T2: What is your definition of “hope” in cases where lung cancer is not curable?
  • T3: Has your definition of “hope” for lung cancer patients changed with time? If so, how?
  • T4: How can we help others find “hope” when they have none? What have you tried that worked?

Please remember to include #LCSM in ALL your tweets so the other chat participants can see them. You can read a primer on participating in the chat here.  Hope you’ll join us!

#LCSM Chat Topic 12/14: #LCSM Community 2017 Highlights, Visions for 2018

By just about any measure, 2017 has been a banner year in lung cancer management for the lung cancer community.  Here is just a partial list of some of the key highlights:

  • Growing use of stereotactic ablative body radiation (SABR) for patients with unresectable early stage disease
  • Increasing momentum for local therapies, including surgery and/or radiation, for isolated residual disease after systemic therapy even for more advanced NSCLC
  • A likely new standard of care for unresectable stage III NSCLC, with addition of immunotherapy, after more than a decade without any treatments proven to improve clinical outcomes
  • Evolving standards for how to best integrate immunotherapy for stage IV NSCLC, with ever-improving survival numbers
  • Significant benefits from shifting later generation EGFR and ALK inhibitor therapies into first line treatment.
  • Mounting evidence to support a role for immunotherapy in treatment of small cell lung cancer and malignant pleural mesothelioma.
  • Hints to help us better define which patients are more or less likely to benefit from immunotherapy.

Still, anybody working in lung cancer remains humbled by our ongoing challenges.  Not only should we remind ourselves and the rest of the world that #433aday in the US alone die of lung cancer, but lung cancer is still terribly under-recognized as the leading cause of cancer death for both women and men in the US and among the leading causes around the world.  This, along with the ever-present stigma throughout the general public that victims of lung cancer are less deserving of support and empathy because of the ties of the disease to tobacco, continues to leave lung cancer woefully underfunded in clinical research.

As we approach the end of 2017, please join #LCSM Community on 12/14 at 8 PM Eastern (5 PM Pacific) to review our 2017 highlights and discuss what we envision for 2018.  Moderator Dr. Jack West (@JackWestMD) will help us cover the following questions:

  • From your personal perspective (doc, pt, caregiver), what were biggest developments in lung cancer in 2017?
  • Has the #LCSM community made meaningful strides in 2017 in overcoming long-standing challenges in how LC is perceived by others?
  • What are most likely big advances in lung cancer mgmt you anticipate or (realistically) hope to see as changes in 2018?
  • As an #LCSM community, what are key shortcomings WE need to address to advance developments in LC? How can we help ourselves?

Please remember to include #LCSM in ALL your tweets so the other chat participants can see them. You can read a primer on participating in the chat here.  Hope you’ll join us!

%d bloggers like this: